Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders 2017
DOI: 10.1016/b978-0-12-802810-0.00004-0
|View full text |Cite
|
Sign up to set email alerts
|

Current Medications for the Treatment of Alzheimer’s Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 11 publications
(3 citation statements)
references
References 24 publications
0
3
0
Order By: Relevance
“…At present, approved pharmacological treatment for AD includes cholinesterase inhibitors (ChEIs) and N-methyl-d-aspartate (NMDA) glutamate receptor antagonists. Moreover, in 2014, FDA also approved a combination of memantine and ChEIs for patients with moderate-to-severe AD [ 8 ].…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…At present, approved pharmacological treatment for AD includes cholinesterase inhibitors (ChEIs) and N-methyl-d-aspartate (NMDA) glutamate receptor antagonists. Moreover, in 2014, FDA also approved a combination of memantine and ChEIs for patients with moderate-to-severe AD [ 8 ].…”
Section: Introductionmentioning
confidence: 99%
“…Further other systemic effects related to cholinergic activity include urinary urgency, bradycardia, and syncope. Because of this, close monitoring of the patient and dose titration has been recommended [ 8 , 10 , 11 ].…”
Section: Introductionmentioning
confidence: 99%
“…Currently, the drugs used for the symptomatic treatment of AD act by limiting the hydrolysis of synaptic acetylcholine [ 9 , 10 ]. This approach has proven to be effective in improving the intellectual functions of patients suffering from AD [ 11 , 12 ]. However, the used drugs cause various adverse effects including hepatotoxicity, vomiting, fatigue, muscle cramps [ 13 , 14 , 15 ].…”
Section: Introductionmentioning
confidence: 99%